Inarigivir

DB15062InvestigationalSmall molecule

Inarigivir is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B...

Mechanism: Pharmacologically active on Nucleotide-binding oligomerization domain-containing protein 2 and Antiviral innate immune response receptor RIG-I
Curator reviewed
Formula / weight: C₂₀H₂₆N₇O₁₀PS · 587.5 g/mol (avg)

Resolves to

Compound

UNIITQ0A9FIV71CAS475650-36-3ChEMBLCHEMBL1084430

Structure

InChIKeyLYMICVBGNUEHGE-FUQPUAIBSA-NSMILESCO[C@@H]1[C@H](OP(S)(=O)OC[C@H]2O[C@H](C[C@@H]2O)N2C=NC3=C2N=CN=C3N)[C@@H](CO)O[C@H]1N1C=CC(=O)NC1=O

Targets

Q9HC29NOD2O95786RIGI

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Inarigivir, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account